TAK875, also widely recognized as Fasiglifam (CAS: 1000413-72-8), stands as a significant chemical entity in the realm of type 2 diabetes research. As a highly selective agonist of the G protein-coupled receptor 40 (GPR40), also known as Free Fatty Acid Receptor 1 (FFAR1), this molecule has undergone extensive investigation for its potential to improve blood sugar control through a novel mechanism of action. NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-quality chemical intermediates such as TAK875 to support cutting-edge pharmaceutical research and development globally.

One of the most compelling aspects of TAK875 is its unique pharmacological profile. Research has demonstrated that TAK875 functions as an ago-allosteric modulator of FFAR1. This implies that it not only exhibits partial agonistic activity but also positively cooperates with endogenous free fatty acids (FFAs) to enhance insulin secretion. This distinctive glucose-dependent insulin release mechanism is particularly advantageous, as it aims to significantly lower the risk of hypoglycemia, a frequent concern with conventional antidiabetic agents like sulfonylureas. Studies have underscored that the insulinotropic effects of TAK875 are notably influenced by plasma FFA levels, highlighting its intricate interaction with the body's natural metabolic signals.

Preclinical and initial clinical studies provided evidence of TAK875's robust glucose-lowering capabilities and its effectiveness in improving both postprandial and fasting hyperglycemia in various diabetic models. Furthermore, investigations into its long-term impact on pancreatic beta cells indicated that TAK875 does not exacerbate fatty acid-induced lipotoxicity, thereby contributing to the preservation of beta-cell function and survival. Its allosteric modulation property offers potential benefits, including greater receptor selectivity and a reduced likelihood of receptor desensitization, making it an intriguing subject for continued exploration into GPCR dynamics and innovative therapeutic strategies.

Chemically, TAK875 has the molecular formula C29H32O7S and a molecular weight of 524.62500. It is characterized by a predicted boiling point of 739.1±60.0 °C and a density of 1.252. NINGBO INNO PHARMCHEM CO.,LTD. provides TAK875 with a purity typically at 97%+, ensuring its suitability for rigorous research and development applications. The compound is stable under normal temperature and pressure and should be stored in a tightly closed container within a cool, dry, and well-ventilated area, away from incompatible substances.

While the journey for novel pharmaceutical compounds from discovery to market is often intricate and subject to evolving safety data and regulatory assessments, TAK875 maintains its stature as a valuable chemical entity for academic and industrial research into FFAR1 mechanisms, diabetes pathophysiology, and allosteric modulation. Its distinctive mode of action continues to provide crucial insights into glucose homeostasis and insulin secretion pathways. For researchers and institutions looking to buy TAK875 or seeking a reliable TAK875 manufacturer and supplier, NINGBO INNO PHARMCHEM CO.,LTD. offers this high-quality intermediate. We are dedicated to providing a competitive price and efficient purchase options for bulk quantities, including 5g, 25g, 100g, 500g, 1kg, and 25kg, to facilitate your scientific advancements. Our unwavering commitment to integrity and quality establishes us as a trusted partner for all your chemical intermediate requirements.